Alpha Tau Highlights Five U.S. Trials Ahead of Key Milestones; Shares Dip

Alpha Tau Medical (NASDAQ: DRTS) highlights five ongoing U.S. clinical trials with multiple data readouts expected in 2026, though shares fell 4.2% on January 29, 2026, amid investor caution over trial timelines and commercialization risks. The trials target recurrent head and neck cancers, pancreatic cancer, and soft tissue sarcomas using its Alpha DaRT radiotherapy technology. Management expects interim safety data from three trials by Q2 2026 and preliminary efficacy results from two others by Q3 2026. Analysts note the company’s cash runway extends into early 2027, but warn that delays or underwhelming data could pressure the stock further. Alpha Tau has no approved products and generated $0 in revenue in 2025.